Aromatase
inhibitors in women who cannot receive adjuvant tamoxifen
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
For
patients where I’m concerned about thromboembolic risks —
and those factors would be history of a thromboembolic event —
clearly I would not even consider the use of tamoxifen and I’m
totally comfortable with the use of Arimidex, for example. Patients
with perhaps not history of deep vein thrombosis but a history of
thrombophlebitis, patients with family history of coagulopathy even
without the patients themselves being worked up for specific coagulopathy.
Patients also who have other risk factors: morbidly obese, sedentary
patients, patients with pre-existing severe edema or lymphadema
of the ipsilateral arm from where they had axillary surgery. There
are many scenarios that I think perhaps the risks might warrant
the alternative use of an aromatase inhibitor as opposed to tamoxifen.
